CoreWeave and Charles River Laboratories see analyst target adjustments

JPMorgan Chase & Co. has increased its price target for CoreWeave from $105.00 to $110.00, maintaining a neutral rating. This adjustment suggests a potential upside of approximately 24.86% from the company's current price. Other analysts have provided varying outlooks, including Piper Sandler with an overweight rating and a $151.00 target, and BNP Paribas Exane with an outperform rating and a $192.00 target.

Separately, Charles River Laboratories International reached a new 52-week high, trading as high as $277.07. Several financial institutions have raised their price targets for the company, including Morgan Stanley and TD Cowen, both of which set targets at $300.00. The stock currently holds a consensus rating of 'Moderate Buy' among research analysts.